Sorin Group (BIT:SRN) touted new European regulatory wins extending use of its Perceval bioprosthetic heart valve and approving a new suite of implantation accessories.  

The Perceval valve, which originally won CE Mark last year, was previously limited to patients aged 75 or older. The new indication lowers the age to 65 for patients with aortic valve stenosis or steno-insufficiency.

The newly approved next-generation surgical instruments aim to ease surgery and minimize surgical trauma and morbidity, according to a press release.

That’s more good news for the European healthcare giant, which earlier this year announced a $14 million buyout of cannula-maker California Medical Technologies.

The cardiac device titan is also looking to boost its footprint in the U.S., where it’s a back-bencher compared with more established competitors like Medtronic (NYSE:MDT), Boston Scientific (NYSE:BSX) and St. Jude Medical (NYSE:STJ).

SRN shares gained 0.4% today, closting at $1.76.